Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Insider	Title	Date	Shares	% Owned	Market Value
Ying Huang	CEO & Director Show All	2023-12-31	64.25K	0.03507%	$3.8M
Corazon Dating Sanders	Independent Director, Independent Non-Executive Director & Member of Scientific Advisory Committee, Co-Chairman of Advisory Board, Director Show All	2023-12-31	19.2K	0.01048%	$1.13M
Patrick Casey	Independent Director Show All	2023-12-31	12.67K	0.00692%	$748.62K
Xiaohui Ji	Independent Director Show All	2023-12-31	9.21K	0.00503%	$544.55K
Lori A. Macomber	Chief Financial Officer Show All	2023-12-31	5.63K	0.00307%	$332.67K
Li Mao
Tomas J. Heyman
Wai Man Yau
Ye Wang
Fangliang Zhang